PBT), a biopharmaceutical company focused on the research and
development of treatments for neurodegenerative disorders, announced today
that the Company will be hosting a conference call with Geoffrey Kempler,
Chairman and CEO, and Dr. Jeffrey Cummings, Chairman of Prana's Research
and Development Advisory Board, on July 31, 2008 at noon EDT (USA time).
The Company will provide a discussion of recent preclinical and clinical
trial highlights and an overview of the ICAD presentations. Members of
Prana's Scientific and Management team will be on the call.
The call will simultaneously be Webcast on Thursday, July 31, 2008 at noon
EDT (USA time). A question-and-answer session will follow management's
presentation. Interested parties may participate in the conference call by
dialing the following numbers approximately five to ten minutes before the
call start time:
+1 877-407-8033 from the US or Canada (toll-free)
+1 201-689-8033 (International)
A live Webcast of the conference call will be available on the Prana Web
site at www.pranabio.com
A replay of the call will be available starting on July 31, 2008, at 3:30
p.m. EDT (USA time) through August 7, 2008 at 11:59 p.m. EDT (USA time).
An archived Webcast of the conference call will be available on the Prana
Web site at www.pranabio.com. Interested parties may access the replay by
dialing the following numbers and entering the account number and
conference ID number below:
+1-877-660-6853 (North America)
+1-201-612-7415 (International)
Account #: 286
Conference ID #: 291849
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into
Alzheimer's disease and other major age-related neurodegenerative
disorders. The company was incorporated in 1997 and listed on the
Australian Stock Exchange in March 2000 and listed on NASDAQ in September
2002. Researchers at prominent international institutions including the
University of Melbourne, the Mental Health Research Institute (Melbourne)
and Massachusetts General Hospital, a teaching hospital of Harvard Medical
School, discovered Prana's technology.
For further information, please visit our web site at www.pranabio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning
of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. The Company has tried to identify such
forward-looking statements by use of such words as "expects," "intends,"
"hopes," "anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not the
exclusive means of identifying such statements. Such statements include,
but are not limited to any statements relating to the Company's drug
development program, including, but not limited to the initiation, progress
and outcomes of clinical trials of the Company's drug development program,
including, but not limited to, PBT2, and any other statements that are not
historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties relating to
the difficulties or delays in financing, development, testing, regulatory
approval, production and marketing of the Company's drug components,
including, but not limited to, PBT2, the ability of the Company to procure
additional future sources of financing, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company's drug compounds, including,
but not limited to, PBT2, that could slow or prevent products coming to
market, the uncertainty of patent protection for the Company's intellectual
property or trade secrets, including, but not limited to, the intellectual
property relating to PBT2, and other risks detailed from time to time in
the filings the Company makes with Securities and Exchange Commission
including its annual reports on From 20-F and its reports on Form 6-K.
Such statements are based on management's current expectations, but actual
results may differ materially due to various factions including those risks
and uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements as a
prediction of actual future results.